Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Recent clinical, regulatory, research and industry developments relating to this disease.
Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2026-06-09Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisResults expected Q4 2026
- 2026-06-09ClinicalSafety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis1
- Mental Disorders1
Leading journals1
- Neurology1
Leading researchers2
- Dalmau J1
- Guasp M1
Affiliations (unnormalised)1
- From the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) (M.G.1
Reference
Authoritative identity, definition & identifiers.
Disorder characterized by symptoms of CATATONIA; HYPOVENTILATION; DYSKINESIAS; ENCEPHALITIS; and SEIZURES followed by a reduced CONSCIOUSNESS. It is often followed by a viral-like prodrome. Many cases are self-limiting and respond well to IMMUNOMODULATORY THERAPIES against the NMDA RECEPTORS antibodies.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.